BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 22808921)

  • 1. Serum levels of pancreatic stone protein (PSP)/reg1A as an indicator of beta-cell apoptosis suggest an increased apoptosis rate in hepatocyte nuclear factor 1 alpha (HNF1A-MODY) carriers from the third decade of life onward.
    Bacon S; Kyithar MP; Schmid J; Rizvi SR; Bonner C; Graf R; Prehn JH; Byrne MM
    BMC Endocr Disord; 2012 Jul; 12():13. PubMed ID: 22808921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of hepatocyte nuclear factor-1A and -4A on pancreatic stone protein/regenerating protein and C-reactive protein gene expression: implications for maturity-onset diabetes of the young.
    Kyithar MP; Bonner C; Bacon S; Kilbride SM; Schmid J; Graf R; Prehn JH; Byrne MM
    J Transl Med; 2013 Jun; 11():156. PubMed ID: 23803251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. INS-1 cells undergoing caspase-dependent apoptosis enhance the regenerative capacity of neighboring cells.
    Bonner C; Bacon S; Concannon CG; Rizvi SR; Baquié M; Farrelly AM; Kilbride SM; Dussmann H; Ward MW; Boulanger CM; Wollheim CB; Graf R; Byrne MM; Prehn JH
    Diabetes; 2010 Nov; 59(11):2799-808. PubMed ID: 20682686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating CD36 is reduced in HNF1A-MODY carriers.
    Bacon S; Kyithar MP; Schmid J; Costa Pozza A; Handberg A; Byrne MM
    PLoS One; 2013; 8(9):e74577. PubMed ID: 24069322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating ghrelin level is higher in HNF1A-MODY and GCK-MODY than in polygenic forms of diabetes mellitus.
    Nowak N; Hohendorff J; Solecka I; Szopa M; Skupien J; Kiec-Wilk B; Mlynarski W; Malecki MT
    Endocrine; 2015 Dec; 50(3):643-9. PubMed ID: 25987348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intima-media thickness and endothelial dysfunction in GCK and HNF1A-MODY patients.
    Szopa M; Osmenda G; Wilk G; Matejko B; Skupien J; Zapala B; Młynarski W; Guzik T; Malecki MT
    Eur J Endocrinol; 2015 Mar; 172(3):277-83. PubMed ID: 25501962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of serum 1,5 anhydroglucitol levels as a clinical test to differentiate subtypes of diabetes.
    Pal A; Farmer AJ; Dudley C; Selwood MP; Barrow BA; Klyne R; Grew JP; McCarthy MI; Gloyn AL; Owen KR
    Diabetes Care; 2010 Feb; 33(2):252-7. PubMed ID: 19933992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multigenerational study on phenotypic consequences of the most common causal variant of HNF1A-MODY.
    Kettunen JLT; Rantala E; Dwivedi OP; Isomaa B; Sarelin L; Kokko P; Hakaste L; Miettinen PJ; Groop LC; Tuomi T
    Diabetologia; 2022 Apr; 65(4):632-643. PubMed ID: 34951657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A single dose of dapagliflozin, an SGLT-2 inhibitor, induces higher glycosuria in GCK- and HNF1A-MODY than in type 2 diabetes mellitus.
    Hohendorff J; Szopa M; Skupien J; Kapusta M; Zapala B; Platek T; Mrozinska S; Parpan T; Glodzik W; Ludwig-Galezowska A; Kiec-Wilk B; Klupa T; Malecki MT
    Endocrine; 2017 Aug; 57(2):272-279. PubMed ID: 28593615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-sensitivity CRP discriminates HNF1A-MODY from other subtypes of diabetes.
    McDonald TJ; Shields BM; Lawry J; Owen KR; Gloyn AL; Ellard S; Hattersley AT
    Diabetes Care; 2011 Aug; 34(8):1860-2. PubMed ID: 21700917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality of life assessment in patients with HNF1A-MODY and GCK-MODY.
    Szopa M; Matejko B; Ucieklak D; Uchman A; Hohendorff J; Mrozińska S; Głodzik W; Zapała B; Płatek T; Solecka I; Sani CM; Małecki MT
    Endocrine; 2019 May; 64(2):246-253. PubMed ID: 30421137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incretin hormones and maturity onset diabetes of the young--pathophysiological implications and anti-diabetic treatment potential.
    Østoft SH
    Dan Med J; 2015 Sep; 62(9):. PubMed ID: 26324089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic profiling in Maturity-onset diabetes of the young (MODY) and young onset type 2 diabetes fails to detect robust urinary biomarkers.
    Gloyn AL; Faber JH; Malmodin D; Thanabalasingham G; Lam F; Ueland PM; McCarthy MI; Owen KR; Baunsgaard D
    PLoS One; 2012; 7(7):e40962. PubMed ID: 22859960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of HNF1A-MODY and HNF4A-MODY in Irish families: phenotypic characteristics and therapeutic implications.
    Kyithar MP; Bacon S; Pannu KK; Rizvi SR; Colclough K; Ellard S; Byrne MM
    Diabetes Metab; 2011 Dec; 37(6):512-9. PubMed ID: 21683639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A decision algorithm to identify patients with high probability of monogenic diabetes due to HNF1A mutations.
    Szopa M; Klupa T; Kapusta M; Matejko B; Ucieklak D; Glodzik W; Zapala B; Sani CM; Hohendorff J; Malecki MT; Skupien J
    Endocrine; 2019 Apr; 64(1):75-81. PubMed ID: 30778899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maturity Onset Diabetes of the Young (MODY) in Tunisia: Low frequencies of GCK and HNF1A mutations.
    Ben Khelifa S; Martinez R; Dandana A; Khochtali I; Ferchichi S; Castaño L
    Gene; 2018 Apr; 651():44-48. PubMed ID: 29408271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of circulating microRNAs in HNF1A-MODY carriers.
    Bonner C; Nyhan KC; Bacon S; Kyithar MP; Schmid J; Concannon CG; Bray IM; Stallings RL; Prehn JH; Byrne MM
    Diabetologia; 2013 Aug; 56(8):1743-51. PubMed ID: 23674172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-inheritance of HNF1a and GCK mutations in a family with maturity-onset diabetes of the young (MODY): implications for genetic testing.
    López-Garrido MP; Herranz-Antolín S; Alija-Merillas MJ; Giralt P; Escribano J
    Clin Endocrinol (Oxf); 2013 Sep; 79(3):342-7. PubMed ID: 23009393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A UK nationwide prospective study of treatment change in MODY: genetic subtype and clinical characteristics predict optimal glycaemic control after discontinuing insulin and metformin.
    Shepherd MH; Shields BM; Hudson M; Pearson ER; Hyde C; Ellard S; Hattersley AT; Patel KA;
    Diabetologia; 2018 Dec; 61(12):2520-2527. PubMed ID: 30229274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apolipoprotein M can discriminate HNF1A-MODY from Type 1 diabetes.
    Mughal SA; Park R; Nowak N; Gloyn AL; Karpe F; Matile H; Malecki MT; McCarthy MI; Stoffel M; Owen KR
    Diabet Med; 2013 Feb; 30(2):246-50. PubMed ID: 23157689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.